PMID- 28320791
OWN - NLM
STAT- MEDLINE
DCOM- 20171226
LR  - 20190202
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 7
IP  - 3
DP  - 2017 Mar 20
TI  - Patient-reported outcomes and associations with pleural effusion in outpatients 
      with heart failure: an observational cohort study.
PG  - e013734
LID - 10.1136/bmjopen-2016-013734 [doi]
LID - e013734
AB  - OBJECTIVES: We aimed to study whether patient-reported outcomes, measured by 
      quality of life (QoL) and functional class, are sensitive to pleural effusion 
      (PLE) in patients with heart failure (HF), and to study changes in QoL and 
      functional class during follow-up of PLE. METHODS: A cohort of 62 patients from 
      an outpatient HF clinic was included. The amount of PLE was quantified using a 
      pocket-sized ultrasound imaging device. Self-reports of QoL and functional class 
      were collected using the Minnesota Living with Heart Failure Questionnaire 
      (MLHFQ) and the New York Heart Association (NYHA) functional classification. 
      RESULTS: At baseline, 26 (42%) patients had PLE of which 19 (31%) patients had 
      moderate to severe amounts of PLE. Patients with no to mild PLE had a lower MLHFQ 
      score (mean 42, SD 21) compared with patients with a moderate to severe amount of 
      PLE (mean 55, SD 24), p=0.03. For 28 patients (45%) with follow-up data, we 
      observed a linear improvement of the MLHFQ-score (3.2, 95% CI 1.2 to 5.1) with 
      each centimetre reduction of PLE. Correspondingly, patient-reported NYHA-class 
      followed the same pattern as the MLHFQ-score. CONCLUSIONS: Our study indicates 
      that patient-reported outcome measures as MLHFQ may be sensitive tools to 
      identify patients with HF at highest risk of symptomatic PLE and that treatment 
      targeting reduction of PLE during follow-up is essential to improvement of QoL 
      and functional capacity of outpatients with HF. TRIAL REGISTRATION NUMBER: 
      NCT01794715; Results.
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not 
      already granted under a licence) please go to 
      http://www.bmj.com/company/products-services/rights-and-licensing/.
FAU - Gundersen, Guri H
AU  - Gundersen GH
AD  - Department of Medicine, Levanger Hospital, Nord-Trondelag Hospital Trust, 
      Levanger, Norway.
FAU - Norekval, Tone M
AU  - Norekval TM
AD  - Department of Heart Disease, Haukeland University Hospital, Bergen, Norway.
AD  - Department of Clinical Science, Faculty of Medicine and Dentistry, University of 
      Bergen, Bergen, Norway.
FAU - Graven, Torbjorn
AU  - Graven T
AD  - Department of Medicine, Levanger Hospital, Nord-Trondelag Hospital Trust, 
      Levanger, Norway.
FAU - Haug, Hilde H
AU  - Haug HH
AD  - Department of Medicine, Levanger Hospital, Nord-Trondelag Hospital Trust, 
      Levanger, Norway.
FAU - Skjetne, Kyrre
AU  - Skjetne K
AD  - Department of Medicine, Levanger Hospital, Nord-Trondelag Hospital Trust, 
      Levanger, Norway.
FAU - Kleinau, Jens O
AU  - Kleinau JO
AD  - Department of Medicine, Levanger Hospital, Nord-Trondelag Hospital Trust, 
      Levanger, Norway.
FAU - Gustad, Lise T
AU  - Gustad LT
AD  - Department of Medicine, Levanger Hospital, Nord-Trondelag Hospital Trust, 
      Levanger, Norway.
AD  - Department of Neuromedicine (INM), Norwegian University of Science and Technology 
      (NTNU), Trondheim, Norway.
AD  - Department of Circulation and Medical Imaging, Faculty of Medicine, Norwegian 
      University of Science and Technology (NTNU), Trondheim, Norway.
FAU - Dalen, Havard
AU  - Dalen H
AD  - Department of Medicine, Levanger Hospital, Nord-Trondelag Hospital Trust, 
      Levanger, Norway.
AD  - Department of Circulation and Medical Imaging, Faculty of Medicine, K.G. Jebsen 
      Centre of Exercise in Medicine, Norwegian University of Science and Technology 
      (NTNU), Trondheim, Norway.
AD  - Department of Cardiology, St. Olavs University Hospital, Trondheim, Norway.
LA  - eng
SI  - ClinicalTrials.gov/NCT01794715
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20170320
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Diuretics)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiotensin-Converting Enzyme Inhibitors/therapeutic use
MH  - Cohort Studies
MH  - Diuretics/therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/complications/psychology/*therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Norway
MH  - Outpatients/*psychology/statistics & numerical data
MH  - *Patient Reported Outcome Measures
MH  - Pleural Effusion/etiology/psychology/*therapy
MH  - Prospective Studies
MH  - Quality of Life/*psychology
MH  - Surveys and Questionnaires
PMC - PMC5372075
OTO - NOTNLM
OT  - pleural effusion
OT  - point of care ultrasound
OT  - quality of life
COIS- Competing interests: HD held a position at the Medical Imaging Laboratory, 
      Norwegian University of Science and Technology (NTNU), a centre of research-based 
      innovation that is funded by the Research Council of Norway and industry. One of 
      the industry partners was GE Vingmed Ultrasound, which contributed to the total 
      budget with 7 million NOK (6%) for the 8-year period 2007-2014.
EDAT- 2017/03/23 06:00
MHDA- 2017/12/27 06:00
PMCR- 2017/03/20
CRDT- 2017/03/22 06:00
PHST- 2017/03/22 06:00 [entrez]
PHST- 2017/03/23 06:00 [pubmed]
PHST- 2017/12/27 06:00 [medline]
PHST- 2017/03/20 00:00 [pmc-release]
AID - bmjopen-2016-013734 [pii]
AID - 10.1136/bmjopen-2016-013734 [doi]
PST - epublish
SO  - BMJ Open. 2017 Mar 20;7(3):e013734. doi: 10.1136/bmjopen-2016-013734.